Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Operating cash flow by Quarter
Operating cash flow (Form 8-K Selected Cash Flow Information, $M) ($M)
Gilead Sciences Operating cash flow: $3,573M in Q2 2026, up 332.0% from a year earlier.
Latest, Q2 2026
3,573
Period ended Jun 30, 2026
Change on a year earlier
+332.0%
827 in Q2 2025
History
26 quarters
Since Q1 2020
Sources
22
Documents cited below
Where the Q2 2026 figure comes from
“|| Net cash provided by operating activities | $ | 3,573 | $ | 827 | $ | 6,117 | $ | 2,584”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Reported in Form 8-K Selected Cash Flow Information.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Gilead Sciences Operating cash flow ($M), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rel-ocf-row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.